Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109385

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

James Shepherd, Christopher J. Packard, Josef R. Patsch, Antonio M. Gotto Jr., and O. David Taunton

Department of Biochemistry, Royal Infirmary, Glasgow, G4 OSF, Scotland

Division of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Shepherd, J. in: PubMed | Google Scholar

Department of Biochemistry, Royal Infirmary, Glasgow, G4 OSF, Scotland

Division of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Packard, C. in: PubMed | Google Scholar

Department of Biochemistry, Royal Infirmary, Glasgow, G4 OSF, Scotland

Division of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Patsch, J. in: PubMed | Google Scholar

Department of Biochemistry, Royal Infirmary, Glasgow, G4 OSF, Scotland

Division of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Gotto, A. in: PubMed | Google Scholar

Department of Biochemistry, Royal Infirmary, Glasgow, G4 OSF, Scotland

Division of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Taunton, O. in: PubMed | Google Scholar

Published May 1, 1979 - More info

Published in Volume 63, Issue 5 on May 1, 1979
J Clin Invest. 1979;63(5):858–867. https://doi.org/10.1172/JCI109385.
© 1979 The American Society for Clinical Investigation
Published May 1, 1979 - Version history
View PDF
Abstract

This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL2 and HDL3 and examines the influence of the drug on the metabolism of the major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II).

The drug lowered plasma cholesterol (15%, P < 0.05) and triglyceride (27%, P < 0.01); the former effect a result of a fall in the amount of cholesterol associated with very low density lipoproteins (31%, P < 0.02) and low density lipoproteins (36%, P < 0.02). Conversely, it raised plasma HDL cholesterol (23%, P < 0.05) and increased (by 345%) the plasma HDL2:HDL3 ratio. The latter derived from an absolute increment (646%) in circulating HDL2, coupled with a fall (47%) in HDL3. This change was not associated with major alterations in the overall cholesterol (free and esterified), triglyceride, phospholipid, or protein content of the subfractions; however, it was accompanied by substantial changes in their protein composition. In particular, the molar ratio of ApoA-I:ApoA-II in HDL3 declined from 2.7:1 to 2.1:1 during nicotinic acid treatment.

Significant perturbations of ApoA-I and ApoA-II metabolism accompanied the drug-induced HDL subfraction redistribution. Specifically, the plasma concentration of ApoA-I rose by 7% (P < 0.05) because of a decrease in its fractional catabolic rate. Moreover, whereas before treatment 6 and 94% of the plasma ApoA-I circulated with HDL2 and HDL3, after commencement of nicotinic acid therapy this distribution became 49 and 51% in HDL2 and HDL3, respectively. ApoA-II was found mainly in HDL3, both before and during nicotinic acid treatment. Administration of the drug caused a 14% reduction in its plasma concentration (P < 0.05), which derived principally from a fall (22%, P < 0.01) in its synthetic rate.

These data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL3 to HDL2 and (b) a reduction in ApoA-II synthesis. Our present understanding of the association between HDL and atherosclerosis indicates that such changes may have prophylactic value in the prevention of coronary artery disease.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 858
page 858
icon of scanned page 859
page 859
icon of scanned page 860
page 860
icon of scanned page 861
page 861
icon of scanned page 862
page 862
icon of scanned page 863
page 863
icon of scanned page 864
page 864
icon of scanned page 865
page 865
icon of scanned page 866
page 866
icon of scanned page 867
page 867
Version history
  • Version 1 (May 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts